Weifang Tang Selected Research

Weifang Tang Research Topics

8	Neoplasms (Cancer) 01/2021 - 07/2012
5	Melanoma (Melanoma, Malignant) 02/2019 - 01/2015
2	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2017
2	Colorectal Neoplasms (Colorectal Cancer) 02/2019 - 04/2017
1	Hematologic Neoplasms (Hematological Malignancy) 08/2022
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 06/2020
1	Carcinoma (Carcinomatosis) 02/2019
1	Thyroid Neoplasms (Thyroid Cancer) 01/2017
1	Accessory Nerve Injuries 01/2016
1	Atrophy 01/2016
1	Fibrosis (Cirrhosis) 01/2016
1	Body Weight (Weight, Body) 01/2015

3	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2016
3	VemurafenibIBA 02/2019 - 01/2015
2	Sorafenib (BAY 43-9006)FDA Link 01/2015 - 01/2015
1	Cyclin-Dependent Kinase 9IBA 08/2022
1	Phenobarbital (Luminal)FDA Link 01/2022
1	MicellesIBA 01/2021
1	4-S-(propionic acid)sulfidocyclophosphamide (PASP)IBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 06/2020
1	motesanib diphosphateIBA 06/2020
1	Phosphotransferases (Kinase)IBA 02/2019
1	Protein Subunits (Protein Subunit)IBA 04/2017
1	plerixafor FDA Link 01/2017
1	Caspase 3 (Caspase-3)IBA 01/2017
1	Caspase 9IBA 01/2017
1	Chemokine ReceptorsIBA 01/2017
1	CCAAT-Enhancer-Binding ProteinsIBA 01/2017
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2017
1	Connective Tissue Growth FactorIBA 01/2016
1	Pharmaceutical PreparationsIBA 01/2016
1	thiazolyl blueIBA 01/2016
1	4-anisyltetrazolium blueIBA 01/2016
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2016
1	Lysine (L-Lysine)FDA Link 01/2016
1	pyridineIBA 01/2015
1	Carbolines (Beta-Carbolines)IBA 07/2012
1	AlkaloidsIBA 07/2012